A preliminary laboratory study conducted by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster (based on human adenovirus serotype 26, the first component of Sputnik V) are effective against the Omicron variant of Covid, providing for better protection when compared to other vaccines.

Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response.

According to the release, the efficacy of mRNA vaccines has proven to be waning, demonstrated by several scientific publications. A Swedish study in The Lancet journal has shown that Pfizer vaccine’s efficacy against Delta is falling to 47% after 4 months, to 29% after 6 months and to 23% after 7 months. A recent study in the US among 65+ years olds demonstrated the decrease in mRNA vaccine effectiveness accelerating against Delta after month 4, reaching a low of approximately 20% in months 5 through 7.

Recognizing the waning efficacy of mRNA vaccines, EU, UK, Greece, South Korea and other countries have recommended reducing the boosting period from 6 to 3 months.

Sputnik Light booster is recommended to strengthen the efficacy of vaccines against Omicron. Boosting by Sputnik Light as well as heterologous boosting can strengthen and lengthen the quickly waning efficacy of many vaccines in light of the combined Delta and Omicron challenge.

Sputnik Light has already been registered in more than 20 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, Philippines, and San Marino). Sputnik V has been authorized in 71 countries with total population of over 4 billion people.